Figure 3. ILC2s are required for development of vasculitis in hypereosinophilic mice.

(A) BAL from ILC2-deficient ILC2^del x IL5Tg mice (representative of 3 mice/group). (B) Eosinophils or (C) ILC2s in BAL of IL-33–treated ILC2^del x IL5Tg. ****P < 0.0001, **P < 0.01, *P < 0.05 by 1-way ANOVA with Sidak post hoc testing. n = 3–11 mice/group. (D) H&E of lungs from representative IL-33–treated IL5Tg or ILC2^del x IL5Tg mice treated with IL-33 shown in A–C (original magnification, ×40). Scale bars: 100 μm. (E) Number of IL-13^Sm13+ cells in lungs of saline-treated or IL-33–treated YYRS Smart13–knock-in mice expressing a modified human CD4 marker from the mouse IL-13 gene locus. ILC2 defined as lin^–, Thy1.2⁺, CD3^–, Arg1^YFP+, Red5⁺. Data are presented as ± SEM. n = 3–4 mice/group. BAL, bronchoalveolar lavage; ILC2s, type 2 innate lymphoid cells.